What is the Return on Assets (ROA) of ImmunoGen this year?
The Return on Assets (ROA) of ImmunoGen is -0.64 undefined this year.
ImmunoGen ROA 2025
ImmunoGen ROA
-0.64
Ticker
IMGN
ISIN
US45253H1014
WKN
878613
In 2025, ImmunoGen's return on assets (ROA) was -0.64, a 0% increase from the 0 ROA in the previous year.
ImmunoGen Aktienanalyse
What does ImmunoGen do?
ImmunoGen Inc is a leading company in the biotechnology industry. The company was founded in 1981 as a research facility. In recent decades, ImmunoGen Inc has specialized in the development of antibody-drug conjugates (ADCs). ADCs are drugs that consist of an antibody and a cytotoxin that specifically targets tumor cells. In this way, cancer cells can be selectively destroyed without damaging surrounding tissue. ImmunoGen Inc has achieved success in recent years, particularly in the development of ADCs against serious cancers such as lung cancer or breast cancer, and it also collaborates with major pharmaceutical companies such as Roche or Bayer. The business model of ImmunoGen Inc, therefore, consists of developing innovative cancer drugs and successfully bringing them to market. Another branch of the company is the development of therapeutics for other diseases such as rheumatoid arthritis or multiple sclerosis. ImmunoGen Inc also utilizes ADCs to selectively destroy disease-specific cells in these cases. In the past, ImmunoGen Inc has successfully launched several products on the market. For example, in 2019, the cancer drug Kadcyla, manufactured by Roche and based on ImmunoGen's ADC technology, was approved by the US Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. The ADC development candidate IMGN632 also shows promising results in the treatment of acute myeloid leukemia and other cancer diseases. The history of ImmunoGen Inc has also been marked by some challenges. In the early years of the company, it faced financial difficulties and sold a large number of shares to an investor in 1999. However, the company remained diligent in research and development and eventually became one of the leading biotech companies in the field of cancer research with the development of ADCs. Nevertheless, the company has also experienced setbacks in the development of products and has had to discontinue several development programs. Despite everything, ImmunoGen Inc is considered a successful company in the biotechnology industry, effectively marketing its innovative solutions in the oncology market. It is also being closely watched to see whether future ADCs will not have to undergo as long development cycles as their predecessors, which can guarantee long-term success for the company. ImmunoGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding ImmunoGen's Return on Assets (ROA)
ImmunoGen's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing ImmunoGen's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider ImmunoGen's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in ImmunoGen’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about ImmunoGen stock
What was the ROA of ImmunoGen compared to the previous year?
The ROA of ImmunoGen has increased by 0% compared to the previous year.
What consequences do high ROA have for investors of ImmunoGen?
A high ROA is advantageous for investors of ImmunoGen, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in ImmunoGen?
A low ROA can be unfavorable for investors of ImmunoGen as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of ImmunoGen affect the company?
An increase in ROA of ImmunoGen can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of ImmunoGen impact the company?
A reduction in the ROA of ImmunoGen can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of ImmunoGen?
Some factors that can influence the ROA of ImmunoGen include revenue, operating costs, asset structure, and industry average.
Why is the ROA of ImmunoGen important for investors?
The ROA of ImmunoGen is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can ImmunoGen take to improve ROA?
To improve ROA, ImmunoGen can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does ImmunoGen pay?
Over the past 12 months, ImmunoGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmunoGen is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmunoGen?
The current dividend yield of ImmunoGen is .
When does ImmunoGen pay dividends?
ImmunoGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmunoGen?
ImmunoGen paid dividends every year for the past 0 years.
What is the dividend of ImmunoGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmunoGen located?
ImmunoGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmunoGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmunoGen from 2/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/6/2025.
When did ImmunoGen pay the last dividend?
The last dividend was paid out on 2/6/2025.
What was the dividend of ImmunoGen in the year 2024?
In the year 2024, ImmunoGen distributed 0 USD as dividends.
In which currency does ImmunoGen pay out the dividend?
The dividends of ImmunoGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmunoGen
Our stock analysis for ImmunoGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmunoGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
